Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome

Endocrine

Volumn 42, Issue 3, 2012, Pages 526-534

  Witchel, Selma F ^a   Recabarren, Sergio E ^b   González, Frank ^c   Diamanti Kandarakis, Evanthia ^d   Cheang, Kai I ^e   Duleba, Antoni J ^f   Legro, Richard S ^g   Homburg, Roy ^h   Pasquali, Renato ⁱ   Lobo, Rogerio A ^j   Zouboulis, Christos C ^k   Kelestimur, Fahrettin ^l   Fruzzetti, Franca ^m   Futterweit, Walter ⁿ   Norman, Robert J ^o   Abbott, David H ^p  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF CONCEPCIÓN   (Chile)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g PENN STATE COLLEGE OF MEDICINE   (United States)

^h TEL AVIV UNIVERSITY   (Israel)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j Och Spine at New York Presbyterian Hospitals   (United States)

^k DESSAU MEDICAL CENTER   (Germany)

^l ERCIYES UNIVERSITY   (Turkey)

^m UNIVERSITY OF PISA   (Italy)

ⁿ MOUNT SINAI MEDICAL CENTER   (United States)

^o UNIVERSITY OF ADELAIDE   (Australia)

^p UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

more..

Author keywords

Advanced glycated end products; Aromatase inhibitors; Clomiphene citrate; Congenital adrenal hyperplasia; Developmental programming; Hirsutism; Inflammation; Lifestyle intervention; Metformin; Statins

Indexed keywords

ANASTROZOLE; ANDROGEN; AROMATASE INHIBITOR; CLOMIFENE CITRATE; CYPROTERONE ACETATE; EFLORNITHINE; FINASTERIDE; FLUTAMIDE; INSULIN SENSITIZING AGENT; LETROZOLE; METFORMIN; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE;

ANOVULATION; ARTICLE; CONGENITAL ADRENAL HYPERPLASIA; DOCTOR PATIENT RELATION; DRUG MECHANISM; FEMALE INFERTILITY; HEALTH BEHAVIOR; HIRSUTISM; HUMAN; INFERTILITY; INFLAMMATION; LIFESTYLE MODIFICATION; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRENATAL PERIOD; PRIORITY JOURNAL; TRANSITION TO ADULT CARE; ADOLESCENT; ADULT; FEMALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; REVIEW;

ADOLESCENT; ADRENAL HYPERPLASIA, CONGENITAL; ADULT; ANDROGENS; ANOVULATION; FEMALE; HIRSUTISM; HUMANS; INFERTILITY, FEMALE; INFLAMMATION; POLYCYSTIC OVARY SYNDROME; PREGNANCY;

EID: 84878250104     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9701-4     Document Type: Article

References (112)

1. B.C. Fauser, B.C. Tarlatzis, R.W. Rebar, R.S. Legro, A.H. Balen, R. Lobo, E. Carmina, J. Chang, B.O. Yildiz, J.S. Laven, J. Boivin, F. Petraglia, C.N. Wijeyeratne, R.J. Norman, A. Dunaif, S. Franks, R.A. Wild, D. Dumesic, K. Barnhart, Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil. Steril. 97, 28-38.e25 (2012)
2. D.H. Abbott, A.F. Tarantal, D.A. Dumesic, Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys. Am. J. Primatol. 71, 776-784 (2009)
3. S. Franks, Polycystic ovary syndrome. N. Engl. J. Med. 333, 853-861 (1995)
4. B.O. Yildiz, E.S. Knochenhauer, R. Azziz, Impact of obesity on the risk for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 93, 162-168 (2008)
5. R. Azziz, C. Marin, L. Hoq, E. Badamgarav, P. Song, Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J. Clin. Endocrinol. Metab. 90, 4650-4658 (2005)
6. E.O. Talbott, J.V. Zborowski, J.R. Rager, K.E. Kip, X. Xu, T.J. Orchard, Polycystic ovarian syndrome (PCOS): a significant contributor to the overall burden of type 2 diabetes in women. J. Womens Health (Larchmt) 16, 191-197 (2007)
7. F. Alvarez-Blasco, J.I. Botella-Carretero, J.L. San Millan, H.F. Escobar-Morreale, Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch. Intern. Med. 166, 2081-2086 (2006)
8. R.A. Wild, E. Carmina, E. Diamanti-Kandarakis, A. Dokras, H.F. Escobar-Morreale, W. Futterweit, R. Lobo, R.J. Norman, E. Talbott, D.A. Dumesic, Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95, 2038-2049 (2010)
9. B. Dilbaz, E. Ozkaya, M. Cinar, E. Cakir, S. Dilbaz, Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. Endocrine 39, 272-277 (2011)
10. Z.J. Chen, H. Zhao, L. He, Y. Shi, Y. Qin, Y. Shi, Z. Li, L. You, J. Zhao, J. Liu, X. Liang, X. Zhao, J. Zhao, Y. Sun, B. Zhang, H. Jiang, D. Zhao, Y. Bian, X. Gao, L. Geng, Y. Li, D. Zhu, X. Sun, J.E. Xu, C. Hao, C.E. Ren, Y. Zhang, S. Chen, W. Zhang, A. Yang, J. Yan, Y. Li, J. Ma, Y. Zhao, Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat. Genet. 43, 55-59 (2011)
11. M.O. Goodarzi, M.R. Jones, X. Li, A.K. Chua, O.A. Garcia, Y.D. Chen, R.M. Krauss, J.I. Rotter, W. Ankener, R.S. Legro, R. Azziz, J.F. Strauss 3rd, A. Dunaif, M. Urbanek, Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J. Med. Genet. 49, 90-95 (2012)
12. H. Zhao, X. Xu, X. Xing, J. Wang, L. He, Y. Shi, Y. Shi, Y. Zhao, Z.J. Chen, Family-based analysis of susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Hum. Reprod. 27, 294-298 (2012)
13. W. Hu, J. Qiao, Expression and regulation of adipocyte fatty acid binding protein in granulosa cells and its relation with clinical characteristics of polycystic ovary syndrome. Endocrine 40, 196-202 (2011)
14. H. Jia, L. Yu, X. Guo, W. Gao, Z. Jiang, Associations of adiponectin gene polymorphisms with polycystic ovary syndrome: a meta-analysis. Endocrine (2012). doi: 10.1007/s12020-012-9605-3
15. R. Saxena, C.K. Welt, Polycystic ovary syndrome is not associated with genetic variants that mark risk of type 2 diabetes. Acta Diabetol. (2012) [Epub ahead of print]
16. R.S. Legro, D. Driscoll, J.F. Strauss 3rd, J. Fox, A. Dunaif, Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc. Natl. Acad. Sci. U.S.A. 95, 14956-14960 (1998)
17. J.M. Vink, S. Sadrzadeh, C.B. Lambalk, D.I. Boomsma, Heritability of polycystic ovary syndrome in a Dutch twin-family study. J. Clin. Endocrinol. Metab. 91, 2100-2104 (2006)
18. A.D. Coviello, R.S. Legro, A. Dunaif, Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J. Clin. Endocrinol. Metab. 91, 492-497 (2006)
19. J.C. Marshall, Obesity in adolescent girls: is excess androgen the real bad actor? J. Clin. Endocrinol. Metab. 91, 393-395 (2006)
20. W.H. Dietz, Health consequences of obesity in youth: childhood predictors of adult disease. Pediatrics 101, 518-525 (1998)
21. A.A. Hedley, C.L. Ogden, C.L. Johnson, M.D. Carroll, L.R. Curtin, K.M. Flegal, Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. J. Am. Med. Assoc. 291, 2847-2850 (2004)
22. C.R. McCartney, K.A. Prendergast, S. Chhabra, C.A. Eagleson, R. Yoo, R.J. Chang, C.M. Foster, J.C. Marshall, The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J. Clin. Endocrinol. Metab. 91, 1714-1722 (2006)
23. C.R. McCartney, Maturation of sleep-wake gonadotrophin-releasing hormone secretion across puberty in girls: potential mechanisms and relevance to the pathogenesis of polycystic ovary syndrome. J. Neuroendocrinol. 22, 701-709 (2010)
24. S.K. Blank, C.R. McCartney, K.D. Helm, J.C. Marshall, Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty. Semin. Reprod. Med. 25, 352-359 (2007)
25. S.K. Blank, C.R. McCartney, J.C. Marshall, The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum. Reprod. Update 12, 351-361 (2006)
26. C.R. McCartney, S.K. Blank, K.A. Prendergast, S. Chhabra, C.A. Eagleson, K.D. Helm, R. Yoo, R.J. Chang, C.M. Foster, S. Caprio, J.C. Marshall, Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J. Clin. Endocrinol. Metab. 92, 430-436 (2007)
27. R.L. Rosenfield, Clinical review: identifying children at risk for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92, 787-796 (2007)
28. D.H. Geller, D. Pacaud, C.M. Gordon, M. Misra, of the Drug and Therapeutics Committee of the Pediatric Endocrine Society, State of the art review: emerging therapies: the use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS). Int. J. Pediatr. Endocrinol. 2011, 9 (2011)
29. S.F. Witchel, R. Azziz, Congenital adrenal hyperplasia. J. Pediatr. Adolesc. Gynecol. 24, 116-126 (2011)
30. R.J. Auchus, S.F. Witchel, K.R. Leight, J. Aisenberg, R. Azziz et al., Guidelines for the development of comprehensive care centers for congenital adrenal hyperplasia: guidance from the CARES foundation initiative. Int. J. Pediatr. Endocrinol. (2011) [Epub 2011 Jan 10]
31. W.C. Chen, C.C. Zouboulis, Hormones and the pilosebaceous unit. Dermatoendocrinology 1, 81-86 (2009)
32. H.J. Teede, M.L. Misso, A.A. Deeks, L.J. Moran, B.G. Stuckey, J.L. Wong, R.J. Norman, Guideline Development Groups, Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med. J. Aust. 195, S65-S112 (2011)
33. D.A. Dumesic, D.H. Abbott, V. Padmanabhan, Polycystic ovary syndrome and its developmental origins. Rev. Endocr. Metab. Disord. 8, 127-141 (2007)
34. V. Padmanabhan, A. Veiga-Lopez, D.H. Abbott, S.E. Recabarren, C. Herkimer, Developmental programming: impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity index and transfer of traits to offspring of overweight females. Endocrinology 151, 595-605 (2010)
35. A.V. Roland, C.S. Nunemaker, S.R. Keller, S.M. Moenter, Prenatal androgen exposure programs metabolic dysfunction in female mice. J. Endocrinol. 207, 213-223 (2010)
36. A. Veiga-Lopez, T.L. Steckler, D.H. Abbott, K.B. Welch, P.S. MohanKumar, D.J. Phillips, K. Refsal, V. Padmanabhan, Developmental programming: impact of excess prenatal testosterone on intrauterine fetal endocrine milieu and growth in sheep. Biol. Reprod. 84, 87-89 (2011)
37. C.M. Bruns, S.T. Baum, R.J. Colman, J.R. Eisner, J.W. Kemnitz, R. Weindruch, D.H. Abbott, Insulin resistance and impaired insulin secretion in prenatally androgenized male rhesus monkeys. J. Clin. Endocrinol. Metab. 89, 6218-6223 (2004)
38. S.E. Recabarren, P.P. Rojas-García, M.P. Recabarren, V.H. Alfaro, R. Smith, V. Padmanabhan, T. Sir-Petermann, Prenatal testosterone excess reduces sperm count and motility. Endocrinology 149, 6444-6448 (2008)
39. P.P. Rojas-García, M.P. Recabarren, L. Sarabia, J. Schön, C. Gabler, R. Einspanier, M. Maliqueo, T. Sir-Petermann, R. Rey, S.E. Recabarren, Prenatal testosterone excess alters Sertoli and germ cell number and testicular FSH receptor expression in rams. Am. J. Physiol. Endocrinol. Metab. 299, E998-E1005 (2010)
40. A.D. Coviello, S. Sam, R.S. Legro, A. Dunaif, High prevalence of metabolic syndrome in first-degree male relatives of women with polycystic ovary syndrome is related to high rates of obesity. J. Clin. Endocrinol. Metab. 94, 4361-4366 (2009)
41. S. Sam, A.D. Coviello, Y.A. Sung, R.S. Legro, A. Dunaif, Metabolic phenotype in the brothers of women with polycystic ovary syndrome. Diabetes Care 31, 1237-1241 (2008)
42. S. Sam, Y.A. Sung, R.S. Legro, A. Dunaif, Evidence for pancreatic beta-cell dysfunction in brothers of women with polycystic ovary syndrome. Metabolism 57, 84-89 (2008)
43. R.S. Legro, A.R. Kunselman, L. Demers, S.C. Wang, R. Bentley-Lewis, A. Dunaif, Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87, 2134-2138 (2002)
44. S.E. Recabarren, R. Smith, R. Rios, M. Maliqueo, B. Echiburú, E. Codner, F. Cassorla, P. Rojas, T. Sir-Petermann, Metabolic profile in sons of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 93, 1820-1826 (2008)
45. D.H. Abbott, C.R. Bruns, D.K. Barnett, A. Dunaif, T.L. Goodfriend, D.A. Dumesic, A.F. Tarantal, Experimentally induced gestational androgen excess disrupts glucoregulation in rhesus monkey dams and their female offspring. Am. J. Physiol. Endocrinol. Metab. 299, E741-E751 (2010)
46. S.C. Kent, C.L. Gnatuk, A.R. Kunselman, L.M. Demers, P.A. Lee, R.S. Legro, Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study. J. Clin. Endocrinol. Metab. 93, 1662-1669 (2008)
47. T. Sir-Petermann, E. Codner, V. Pérez, B. Echiburú, M. Maliqueo, A. Ladrón de Guevara, J. Preisler, N. Crisosto, F. Sánchez, F. Cassorla, S. Bhasin, Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 94, 1923-1930 (2009)
48. J.A. Barry, A.R. Kay, R. Navaratnarajah, S. Iqbal, J.E. Bamfo, A.L. David, M. Hines, P.J. Hardiman, Umbilical vein testosterone in female infants born to mothers with polycystic ovary syndrome is elevated to male levels. J. Obstet. Gynaecol. 30, 444-446 (2010)
49. H. Anderson, N. Fogel, S.K. Grebe, R.J. Singh, R.L. Taylor, A. Dunaif, Infants of women with polycystic ovary syndrome have lower cord blood androstenedione and estradiol levels. J. Clin. Endocrinol. Metab. 95, 2180-2186 (2010)
50. N. Xu, S. Kwon, D.H. Abbott, D.H. Geller, D.A. Dumesic, R. Azziz, X. Guo, M.O. Goodarzi, Epigenetic mechanism underlying the development of polycystic ovary syndrome (PCOS)-like phenotypes in prenatally androgenized rhesus monkeys. PLoS One 6(11), e27286 (2011)
51. D.R. Stewart, B.A. Dombroski, M. Urbanek, W. Ankener, K.G. Ewens, J.R. Wood, R.S. Legro, J.F. Strauss 3rd, A. Dunaif, R.S. Spielman, Fine mapping of genetic susceptibility to polycystic ovary syndrome on chromosome 19p13.2 and tests for regulatory activity. J. Clin. Endocrinol. Metab. 91, 4112-4117 (2006)
52. K.G. Ewens, D.R. Stewart, W. Ankener, M. Urbanek, J.M. McAllister, C. Chen, K.M. Baig, S.C. Parker, E.H. Margulies, R.S. Legro, A. Dunaif, J.F. Strauss 3rd, R.S. Spielman, Family-based analysis of candidate genes for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 95, 2306-2315 (2010)
53. N. Hatzirodos, R.A. Bayne, H.F. Irving-Rodgers, K. Hummitzsch, L. Sabatier, S. Lee, W. Bonner, M.A. Gibson, W.E. Rainey, B.R. Carr, H.D. Mason, D.P. Reinhardt, R.A. Anderson, R.J. Rodgers, Linkage of regulators of TGF-β activity in the fetal ovary to polycystic ovary syndrome. FASEB J. 25, 2256-2265 (2011)
54. T. Massam-Wu, M. Chiu, R. Choudhury, S.S. Chaudhry, A.K. Baldwin, A. McGovern, C. Baldock, C.A. Shuttleworth, C.M. Klelty, Assembly of fibrillin microfibrils governs extracellular deposition of latent TGF beta. J. Cell Sci. 123(Pt 17), 3006-3018 (2010)
55. G. Sengle, R.N. Ono, T. Sasaki, L.Y. Sakai, Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability. J. Biol. Chem. 286, 5087-5099 (2011)
56. B. Kruse, F.G. Riepe, N. Krone, H.A.G. Bosinski, S. Kloehn, C.J. Partsch, W.G. Sippell, H. Mönig, Congenital adrenal hyperplasia - how to improve the transition from adolescence to adult life. Exp. Clin. Endocrinol. Diabetes 112, 343-355 (2004)
57. G.S. Conway, Congenital adrenal hyperplasia: adolescence and transition. Horm. Res. 68(suppl 5), 155-157 (2007)
58. S.D. Grosse, M.S. Schechter, R. Kulkarni, M.A. Lloyd-Puryear, B. Strickland, E. Trevathan, Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics 123, 407-412 (2009)
59. D. Rosen, Between two worlds: bridging the cultures of child health and adult medicine. J. Adolesc. Health 17, 10-16 (1995)
60. G.M. Kieckhefer, C.M. Trahms, Supporting development of children with chronic conditions: from compliance toward shared management. Pediatr. Nurs. 26, 354-363 (2000)
61. E. Carmina, S.E. Oberfield, R.A. Lobo, The diagnosis of polycystic ovary syndrome in adolescents. Am. J. Obstet. Gynecol. 203, 201.e1-5 (2010)
62. A. Lindholm, C. Blomquist, M. Bixo, I. Dahlbom, T. Hansson, I. Sundström Poromaa, J. Burén, No difference in markers of adipose tissue inflammation between overweight women with polycystic ovary syndrome and weight-matched controls. Hum. Reprod. 26, 1478-1485 (2011)
63. D. Glintborg, M. Andersen, B. Richelsen, J.M. Bruun, Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. Clin. Endocrinol. (Oxf) 715, 652-658 (2009)
64. H.F. Escobar-Morreale, M. Luque-Ramírez, F. González, Circulating inflammatory markers in polycystic ovary symdrome: a systematic review and metaanalysis. Fertil. Steril. 95, 1048-1058.e1-2 (2011)
65. K.A. Toulis, D.G. Goulis, G. Mintziori, E. Kintiraki, E. Eukarpidis, S.A. Mouratoglou, A. Pavlaki, S. Stergianos, M. Poulasouchidou, T.G. Tzellos, A. Makedos, M. Chourdakis, B.C. Tarlatzis, Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum. Reprod. Update 17, 741-760 (2011)
66. F. González, Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 77, 300-305 (2012)
67. F. Gonzalez, K.S. Nair, J.K. Daniels, E. Basal, J.M. Schimke, Hyperandrogenism sensitizes mononuclear cells to promote glucose-induced inflammation in lean reproductive-age women. Am. J. Physiol. Endocrinol. Metab. 302, E297-E306 (2012)
68. R. Ramasamy, S.J. Vannucci, S.S. Yan, K. Herold, S.F. Yan, A.M. Schmidt, Advanced glycation end products and RAGE: a common threat in aging, diabetes, neurodegeneretion, and inflammation. Glycobiology 15, 16R-28R (2005)
69. E. Diamanti-Kandarakis, I. Katsikis, C. Piperi, E. Kandaraki, A. Piouka, A.G. Papavassillou, D. Panidis, Increased serum advanced glycation end products is a distinct finding in lean women with PCOS. Clin. Endocrinol. (Oxf) 69, 634-641 (2008)
70. E. Diamanti-Kandarakis, A. Piouka, S. Livadas, C. Piperi, I. Katsikis, A.G. Papavassillou, D. Panidis, Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. Eur. J. Endocrinol. 160, 847-853 (2009)
71. E. Diamanti-Kandarakis, C. Piperi, E. Patsouris, P. Korkolopoulou, D. Panidis, L. Pawelczyk, A.G. Papavassiliou, A.J. Duleba, Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem. Cell Biol. 127, 581-589 (2007)
72. K.K. Papachroni, C. Piperi, G. Levidou, P. Korkolopoulou, L. Pawelczyk, E. Diamanti-Kandarakis, A.G. Papavassiliou, Lysyl oxidase interacts with AGE signalling to modulate collagen synthesis in polycystic ovarian tissue. J. Cell Mol. Med. 14, 2460-2469 (2010)
73. I.J. Rzepczynska, P.C. Piotrowski, D.H. Wong, A.B. Cress, J. Villanueva, A.J. Duleba, Role of isoprenylation in simvastatin-induced inhibition of ovarian theca-interstitial growth in the rat. Biol. Reprod. 81, 850-855 (2009)
74. D. Izquierdo, N. Foyouzi, J. Kwintkiewicz, A.J. Duleba, Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil. Steril. 82(Suppl 3), 1193-1197 (2004)
75. A. Sokalska, P.C. Piotrowski, I.J. Rzepczynska, A. Cress, A.J. Duleba, Statins inhibit growth of human theca-interstitial cells in PCOS and non-PCOS tissues independently of cholesterol availability. J. Clin. Endocrinol. Metab. 95, 5390-5394 (2010)
76. B. Banaszewska, L. Pawelczyk, R.Z. Spaczynski, A.J. Duleba, Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J. Clin. Endocrinol. Metab. 96, 3493-3501 (2011)
77. A.J. Duleba, B. Banaszewska, R.Z. Spaczynski, L. Pawelczyk, Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil. Steril. 85, 996-1001 (2006)
78. C. Kaya, S.D. Cengiz, B. Berker, S. Demirtas, M. Cesur, G. Erdogan, Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertil. Steril. 92, 635-642 (2009)
79. T. Sathyapalan, E.S. Kilpatrick, A.M. Coady, S.L. Atkin, The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J. Clin. Endocrinol. Metab. 94, 103-108 (2009)
80. W.C. Knowler, E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker, D.M. Nathan, Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002)
81. L.J. Moran, R. Pasquali, H.J. Teede, K.M. Hoeger, R.J. Norman, Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil. Steril. 92, 1966-1982 (2009)
82. L.J. Moran, M. Noakes, P.M. Clifton, R.J. Norman, The use of anti-mullerian hormone in predicting menstrual response after weight loss in overweight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92, 3796-3802 (2007)
83. K.I. Cheang, J.M. Huszar, A.M. Best, S. Sharma, P.A. Essah, J.E. Nestler, Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. Diab. Vasc. Dis. Res. 6, 110-119 (2009)
84. K.A. Jablonski, J.B. McAteer, P.I. de Bakker, P.W. Franks, T.I. Pollin, R.L. Hanson, R. Saxena, S. Fowler, A.R. Shuldiner, W.C. Knowler, D. Altshuler, J.C. Florez, Diabetes Prevention Program Research Group, Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 59, 2672-2681 (2010)
85. A. Gambineri, F. Tomassoni, D.I. Gasparini, A. Di Rocco, V. Mantovani, U. Pagotto, P. Altieri, S. Sanna, A.M. Fulghesu, R. Pasquali, Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 95, E204-E208 (2010)
86. T. Sathyapalan, L.W. Cho, E.S. Kilpatrick, A.M. Coady, S.L. Atkin, A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. Clin. Endocrinol. (Oxf) 69, 931-935 (2008)
87. G.M. Eid, D.R. Cottam, L.M. Velcu, S.G. Mattar, M.T. Korytkowski, G. Gosman, P. Hindi, P.R. Schauer, Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg. Obes. Relat. Dis. 1, 77-80 (2005)
88. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Consensus on infertility treatment related to polycystic ovary syndrome. Fertil. Steril. 89, 505-522 (2008)
89. H. Abu Hashim, M. El-Shafei, A. Badawy, A. Wafa, H. Zaglol, Does laparoscopic ovarian diathermy change clomiphene-resistant PCOS into clomiphene-sensitive? Arch. Gynecol. Obstet. 284, 503-507 (2011)
90. N.P. Johnson, A.W. Stewart, J. Falkiner, C.M. Farquhar, S. Milsom, V.P. Singh, Q.L. Okonkwo, K.L. Buckingham, REACT-NZ (REproduction And Collaborative Trials in New Zealand), a multi-centre fertility trials group, PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Hum. Reprod. 25, 1675-1683 (2010)
91. N.P. Polyzos, S. Tzioras, A.M. Badawy, A. Valachis, C. Dritsas, D. Mauri, Aromatase inhibitors for female infertility: a systematic review of the literature. Reprod. Biomed. Online 19, 456-471 (2009)
92. T.D. Vause, A.P. Cheung, S. Sierra, P. Claman, J. Graham, J.A. Guillemin, L. Lapensée, S. Steward, B.C. Wong, Society of Obstetricians and Gynaecologists of Canada, Ovulation induction in polycystic ovary syndrome: No. 242, May 2010. Int. J. Gynaecol. Obstet. 111, 95-100 (2010)
93. D. Tredway, J.C. Schertz, D. Bock, G. Hemsey, M.P Diamond, Anastrozole vs. clomiphene citrate in infertile women with ovulatory dysfunction: a phase II, randomized, dose-finding study. Fertil. Steril. 95, 1720-4.e1-8 (2011)
94. T. Tulandi, J. Martin, R. Al-Fadhli, N. Kabli, R. Forman, J. Hitkari, C. Librach, E. Greenblatt, R.F. Casper, Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil. Steril. 85, 1761-1765 (2006)
95. S. Palomba, A. Falbo, F. Zullo, F. Orio Jr, Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr. Rev. 30, 1-50 (2009)
96. R. Pasquali, A. Gambineri, U. Pagotto, The impact of obesity on reproduction in women with polycystic ovary syndrome. Br. J. Obstet. Gynecol. 113, 1148-1159 (2006)
97. E. Diamanti-Kandarakis, C.D. Christakou, E. Kandaraki, F.N. Economou, Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur. J. Endocrinol. 162, 193-212 (2010)
98. R.S. Legro, H.X. Barnhart, W.D. Schlaff, B.R. Carr, M.P. Diamond, S.A. Carson, M.P. Steinkampf, C. Coutifaris, P.G. McGovern, N.A. Cataldo, G.G. Gosman, J.E. Nestler, L.C. Giudice, P.C. Leppert, E.R. Myers, Cooperative Multicenter Reproductive Medicine Network. Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome. N. Engl. J. Med. 356, 551-566 (2007)
99. S. Palomba, R. Pasquali, F. Orio Jr, J.E. Nestler, Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. Clin. Endocrinol. (Oxf) 70, 311-321 (2009)
100. A.A. Creanga, H.M. Bradley, C. McCormick, C.T. Witkop, Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet. Gynecol. 111, 959-968 (2008)
101. S. Franks, When should an insulin sensitizing agent used in the treatment of polycystic ovary syndrome? Clin. Endocrinol. (Oxf) 74, 148-151 (2011)
102. E. Makrantonaki, C.C. Zouboulis, Androgens and ageing of the skin. Curr. Opin. Endocrinol. Diabetes Obes. 16, 240-245 (2009)
103. C.C. Zouboulis, The human skin as a hormone target and an endocrine gland. Hormones (Athens) 3, 9-26 (2004)
104. C.C. Zouboulis, The skin as an endocrine organ. Dermatoendocrinology 1, 250-252 (2009)
105. C.C. Zouboulis, W.C. Chen, M.J. Thornton, K. Qin, R. Rosenfield, Sexual hormones in human skin. Horm. Metab. Res. 39, 85-95 (2007)
106. A. Drosdzol, V. Skrzypulec, R. Plinta, Quality of life, mental health and self-esteem in hirsute adolescent females. J. Psychosom. Obstet. Gynaecol. 31, 168-175 (2010)
107. H.F. Escobar-Morreale, E. Carmina, D. Dewailly, A. Gambineri, F. Kelestimur, P. Moghetti, M. Pugeat, J. Qiao, C.N. Wijeyaratne, S.F. Witchel, R.J. Norman, Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum. Reprod. Update 18, 146-170 (2012)
108. A. Dokras, Mood and anxiety disorders in women with PCOS. Steroids 77, 338-341 (2012)
109. R. Paparodis, A. Dunaif, The Hirsute woman: challenges in evaluation and management. Endocr. Pract. 17, 807-818 (2011)
110. F. Lumachi, S.M. Basso, Medical treatment of hirsutism in women. Curr. Med. Chem. 17, 2530-2538 (2010)
111. R. Sinclair, M. Patel, T.L. Dawson Jr, A. Yazdabadi, L. Yip, A. Perez, N.W. Rufaut, Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Br. J. Dermatol. 165(Suppl 3), 12-18 (2011)
112. M. Yamaoka, T. Hara, T. Hitaka, T. Kaku, T. Takeuchi, J. Takahashi, S. Asahi, H. Miki, A. Tasaka, M. Kusaka, Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J. Steroid. Biochem. Mol. Biol. 129, 115-128 (2012)